Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mepolizumab and Physical Activity in Severe Asthma
Sponsor: University Hospital, Lille
Summary
Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.
Official title: Evolution of Physical Activity in Severe Asthmatic Patients Treated With Mepolizumab
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
102
Start Date
2023-02-02
Completion Date
2025-07-02
Last Updated
2024-05-23
Healthy Volunteers
No
Conditions
Locations (1)
Lille University Hospital
Lille, France